Certara (NASDAQ:CERT – Get Rating) will release its earnings data after the market closes on Tuesday, August 9th. Analysts expect Certara to post earnings of $0.11 per share for the quarter. Certara has set its FY22 guidance at $0.48-0.53 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.
Certara (NASDAQ:CERT – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $0.11 EPS for the quarter, meeting analysts’ consensus estimates of $0.11. Certara had a negative net margin of 4.02% and a positive return on equity of 3.56%. The company had revenue of $81.60 million for the quarter, compared to analyst estimates of $79.88 million. During the same quarter last year, the firm posted $0.06 earnings per share. The company’s quarterly revenue was up 22.3% compared to the same quarter last year. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Certara Trading Up 0.1 %
Shares of CERT stock opened at $23.02 on Tuesday. Certara has a 1 year low of $16.17 and a 1 year high of $45.48. The firm’s fifty day simple moving average is $20.80 and its 200 day simple moving average is $21.59. The firm has a market capitalization of $3.68 billion, a P/E ratio of -287.75, a price-to-earnings-growth ratio of 0.78 and a beta of 1.01. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.28.
Analyst Upgrades and Downgrades
Insider Buying and Selling
In related news, major shareholder Avatar Parent L.P. Eqt sold 1,500,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $19.00, for a total transaction of $28,500,000.00. Following the transaction, the insider now owns 35,958,939 shares in the company, valued at approximately $683,219,841. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Certara news, major shareholder Avatar Parent L.P. Eqt sold 1,500,000 shares of the business’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $19.00, for a total transaction of $28,500,000.00. Following the completion of the sale, the insider now directly owns 35,958,939 shares of the company’s stock, valued at approximately $683,219,841. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $19.16, for a total value of $191,600.00. Following the sale, the insider now directly owns 88,490 shares of the company’s stock, valued at $1,695,468.40. The disclosure for this sale can be found here. 4.02% of the stock is owned by corporate insiders.
Institutional Trading of Certara
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Captrust Financial Advisors raised its holdings in Certara by 135.8% during the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company’s stock worth $99,000 after purchasing an additional 2,665 shares during the last quarter. MetLife Investment Management LLC bought a new stake in shares of Certara in the 1st quarter valued at about $111,000. PNC Financial Services Group Inc. increased its stake in shares of Certara by 18.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,841 shares of the company’s stock valued at $126,000 after acquiring an additional 905 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in shares of Certara in the 1st quarter valued at about $218,000. Finally, Hsbc Holdings PLC increased its stake in shares of Certara by 8.5% in the 1st quarter. Hsbc Holdings PLC now owns 11,969 shares of the company’s stock valued at $261,000 after acquiring an additional 941 shares during the last quarter. 52.08% of the stock is owned by institutional investors.
Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
- Get a free copy of the StockNews.com research report on Certara (CERT)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook Brightens
- Deep Value High Yield Newell Brands Is Ready To Bottom
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.